NEW YORK (GenomeWeb) – Ovation and Coriell Life Sciences said today that they have agreed to integrate their respective data management and reporting technologies into a single platform for sample and workflow management, genetic data interpretation, and external client communication.
Ovation's main products are a lab service for the tracking of samples, workflows, and processes, and a research service for facilitating collaboration and data sharing between separate teams. Coriell — a for-profit spinoff of the Coriell Institute for Medical Research — specializes in the storage, interpretation, and exchange of genomic data.
The companies said that they will initially focus on pharmacogenomics and women's health, and later expand into cancer genomics, infectious disease diagnosis, and other areas of personalized medicine. Additional terms of the deal were not disclosed.
"With Coriell Life Sciences, we're able to provide our customers with a comprehensive, cloud-based platform for the management of genomic data, genomic interpretation, and reporting that presents only the most valuable and relevant clinical data," Ovation CEO Barry Wark said in a statement. "This partnership will allow our customer labs to bring payors and providers the single most efficient resource for accurately determining drug efficacy across a patient’s often complex medication regimen."
Ovation and Coriell also said they intend to forge additional partnerships for technologies that can be included in their combined platform.
In late 2016, Coriell signed an agreement with Psyche Systems to develop an end-to-end sample management and interpretation and reporting system for pharmacogenomics and women's health molecular diagnostics.